Ye-Ting Wu, Xiao-Juan Ran, Qi-Zhe Li, Yi-Qi Wu, Xiao-Xu Shen, Mao Mu, Quan Zhang
{"title":"肝癌患者血清CXC趋化因子配体13水平及临床意义","authors":"Ye-Ting Wu, Xiao-Juan Ran, Qi-Zhe Li, Yi-Qi Wu, Xiao-Xu Shen, Mao Mu, Quan Zhang","doi":"10.21037/tcr-24-1306","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CXC chemokine ligand 13 (CXCL13) serves as the ligand for chemokine receptor 5 (CXCR5), The CXCL13/CXCR5 signaling axis plays a crucial role in the pathogenesis and progression of various malignancies. This study aimed to assess the expression and role of serum CXCL13 in patients with hepatocellular carcinoma (HCC) and explore its clinical significance in the diagnosis, treatment, and prognosis evaluation of HCC.</p><p><strong>Methods: </strong>Serum samples and clinical data were collected from 74 HCC patients, 51 cirrhosis patients, and 53 healthy controls. The expression level of serum CXCL13 was measured using enzyme-linked immunosorbent assay (ELISA). Statistical software was employed to analyze the relationship between CXCL13 levels and clinicopathological features as well as laboratory indicators. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of CXCL13 and alpha-fetoprotein (AFP) for HCC.</p><p><strong>Results: </strong>The level of serum CXCL13 in the HCC group (275.96±145.35 pg/mL) was significantly higher than that in the cirrhosis group (172.11±142.78 pg/mL) and healthy control group (58.83±41.29 pg/mL). The level of CXCL13 in HCC patients with tumor node metastasis (TNM) stage III-IV was significantly higher than that in those with TNM stage I-II, as well as positively correlated with γ-glutamyltransferase (GGT) and model for end-stage liver disease (MELD) values. The area under the ROC curve for CXCL13, AFP, and the combination of CXCL13 with AFP were 0.819, 0.813, and 0.885 respectively. The sensitivity and specificity of the combined CXCL13 with AFP were 88.9% and 77.9% respectively. Moreover, the diagnostic efficacy of combining CXCL13 with AFP was significantly superior to that of using either CXCL13 or AFP alone.</p><p><strong>Conclusions: </strong>The expression of CXCL13 is upregulated in HCC patients and associated with tumor size, metastasis, GGT, and MELD score. Combining serum CXCL13 with AFP may hold clinical value to the diagnosis of HCC.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 1","pages":"424-433"},"PeriodicalIF":1.7000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833404/pdf/","citationCount":"0","resultStr":"{\"title\":\"Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.\",\"authors\":\"Ye-Ting Wu, Xiao-Juan Ran, Qi-Zhe Li, Yi-Qi Wu, Xiao-Xu Shen, Mao Mu, Quan Zhang\",\"doi\":\"10.21037/tcr-24-1306\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>CXC chemokine ligand 13 (CXCL13) serves as the ligand for chemokine receptor 5 (CXCR5), The CXCL13/CXCR5 signaling axis plays a crucial role in the pathogenesis and progression of various malignancies. This study aimed to assess the expression and role of serum CXCL13 in patients with hepatocellular carcinoma (HCC) and explore its clinical significance in the diagnosis, treatment, and prognosis evaluation of HCC.</p><p><strong>Methods: </strong>Serum samples and clinical data were collected from 74 HCC patients, 51 cirrhosis patients, and 53 healthy controls. The expression level of serum CXCL13 was measured using enzyme-linked immunosorbent assay (ELISA). Statistical software was employed to analyze the relationship between CXCL13 levels and clinicopathological features as well as laboratory indicators. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of CXCL13 and alpha-fetoprotein (AFP) for HCC.</p><p><strong>Results: </strong>The level of serum CXCL13 in the HCC group (275.96±145.35 pg/mL) was significantly higher than that in the cirrhosis group (172.11±142.78 pg/mL) and healthy control group (58.83±41.29 pg/mL). The level of CXCL13 in HCC patients with tumor node metastasis (TNM) stage III-IV was significantly higher than that in those with TNM stage I-II, as well as positively correlated with γ-glutamyltransferase (GGT) and model for end-stage liver disease (MELD) values. The area under the ROC curve for CXCL13, AFP, and the combination of CXCL13 with AFP were 0.819, 0.813, and 0.885 respectively. The sensitivity and specificity of the combined CXCL13 with AFP were 88.9% and 77.9% respectively. Moreover, the diagnostic efficacy of combining CXCL13 with AFP was significantly superior to that of using either CXCL13 or AFP alone.</p><p><strong>Conclusions: </strong>The expression of CXCL13 is upregulated in HCC patients and associated with tumor size, metastasis, GGT, and MELD score. Combining serum CXCL13 with AFP may hold clinical value to the diagnosis of HCC.</p>\",\"PeriodicalId\":23216,\"journal\":{\"name\":\"Translational cancer research\",\"volume\":\"14 1\",\"pages\":\"424-433\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833404/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational cancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tcr-24-1306\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-24-1306","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Level and clinical significance of serum CXC chemokine ligand 13 in patients with hepatocellular carcinoma.
Background: CXC chemokine ligand 13 (CXCL13) serves as the ligand for chemokine receptor 5 (CXCR5), The CXCL13/CXCR5 signaling axis plays a crucial role in the pathogenesis and progression of various malignancies. This study aimed to assess the expression and role of serum CXCL13 in patients with hepatocellular carcinoma (HCC) and explore its clinical significance in the diagnosis, treatment, and prognosis evaluation of HCC.
Methods: Serum samples and clinical data were collected from 74 HCC patients, 51 cirrhosis patients, and 53 healthy controls. The expression level of serum CXCL13 was measured using enzyme-linked immunosorbent assay (ELISA). Statistical software was employed to analyze the relationship between CXCL13 levels and clinicopathological features as well as laboratory indicators. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of CXCL13 and alpha-fetoprotein (AFP) for HCC.
Results: The level of serum CXCL13 in the HCC group (275.96±145.35 pg/mL) was significantly higher than that in the cirrhosis group (172.11±142.78 pg/mL) and healthy control group (58.83±41.29 pg/mL). The level of CXCL13 in HCC patients with tumor node metastasis (TNM) stage III-IV was significantly higher than that in those with TNM stage I-II, as well as positively correlated with γ-glutamyltransferase (GGT) and model for end-stage liver disease (MELD) values. The area under the ROC curve for CXCL13, AFP, and the combination of CXCL13 with AFP were 0.819, 0.813, and 0.885 respectively. The sensitivity and specificity of the combined CXCL13 with AFP were 88.9% and 77.9% respectively. Moreover, the diagnostic efficacy of combining CXCL13 with AFP was significantly superior to that of using either CXCL13 or AFP alone.
Conclusions: The expression of CXCL13 is upregulated in HCC patients and associated with tumor size, metastasis, GGT, and MELD score. Combining serum CXCL13 with AFP may hold clinical value to the diagnosis of HCC.
期刊介绍：
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
